Formula C22H16N4O3 | ||
SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7. (It is NOT an ALK inhibitor).
Contents
In-vitro studies
It also suppressed the TGF-beta-induced proliferation of osteosarcoma cells in humans.
As of January 2016 There are no clinical trials registered for SB-431542 for cancer or any other indication.
In vitro use
The treatment with SB431542 is a robust, clinically applicable, and efficient system for generating mesenchymal stem/stromal cells (MSCs) from human iPSCs.
References
SB-431542 Wikipedia(Text) CC BY-SA